455 E. MEDICAL CENTER BLVD, HOUSTON, TX
Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws
Announces Pricing of $3 Million Public Offering
CFO Salary Increase - Jason D. Davis Receives $400,000 Base Salary
FibroBiologics, Inc. Holds Special Meeting; Reverse Stock Split Approved
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Amended Annual Report
FY 2024
Q3
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement